Positive Study Results

Futura Medical PLC
09 August 2007

For immediate release                                              9 August 2007



                               Futura Medical Plc
                          ('Futura' or 'the Company')

                  Successful results from CSD500 condom study

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative
products for the consumer healthcare market, is pleased to announce positive
results from a user study of CSD500, Futura's novel product to help men maintain
a full erection when wearing a condom. The study, equally funded by Futura and
its marketing and distribution partner SSL International plc (SSL), successfully
met its primary endpoint of demonstrating a firmer erection through the use of
the CSD500 condom compared with a standard condom. This result was highly
statistically significant.

The study's secondary endpoints of increased penile size and a longer-lasting
sexual experience also revealed positive, statistically significant data. These
results from the double-blind, randomised, cross-over study will complete the
regulatory package for CSD500.

The study included 108 healthy couples, the men of which had at some time
experienced a loss or partial loss of erection whilst using standard condoms.  A
good safety and tolerability profile was reported for CSD500.

James Barder, Futura's Chief Executive, said: 'I am delighted by these highly
statistically significant study results, which give us confidence that the
CSD500 product will gain marketing approval and, once launched, be a commercial
success.  We look forward to continuing to work closely with SSL.'

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive                          Tel: [phone]
mail to: [e-mail]                www.futuramedical.co.uk

Canaccord Adams                                        Tel: [phone]
Mark Ashurst

For any media enquiries please contact:
Buchanan Communications                               Tel: [phone]
Mark Court / Rebecca Dietrich



Notes

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare.  The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.

The information pursuant to AIM rule 26 is now available at Futura's website:
www.futuramedical.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange